Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma.
Understanding the biology and molecular pathogenesis of ovarian epithelial cancer (EOC) is key to developing improved diagnostic and prognostic indicators and effective therapies. Although research has traditionally focused on the hypothesis that high-grade serous carcinoma (HGSC) arises from the ovarian surface epithelium (OSE), recent studies suggest that additional sites of origin exist and a substantial proportion of cases may arise from precursor lesions located in the Fallopian tubal epithelium (FTE). In FTE cells, the transcription factor PAX8 is a marker of the secretory cell lineage and its expression is retained in 96% of EOC. We have recently reported that PAX8 is involved in the tumorigenic phenotype of ovarian cancer cells. In this study, to uncover genes and pathways downstream of PAX8 involved in ovarian carcinoma we have determined the molecular profiles of ovarian cancer cells and in parallel of Fallopian tube epithelial cells by means of a silencing approach followed by an RNA-seq analysis. Interestingly, we highlighted the involvement of pathways like WNT signaling, epithelial-mesenchymal transition, p53 and apoptosis. We believe that our analysis has led to the identification of candidate genes and pathways regulated by PAX8 that could be additional targets for the therapy of ovarian carcinoma.
IEOS, Institute of Experimental Endocrinology and Oncology "G. Salvatore", National Research Council, Naples, Italy.
Tiziana
T
de Cristofaro
IEOS, Institute of Experimental Endocrinology and Oncology "G. Salvatore", National Research Council, Naples, Italy.
Tina
T
Di Palma
IEOS, Institute of Experimental Endocrinology and Oncology "G. Salvatore", National Research Council, Naples, Italy.|Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
Amata Amy
AA
Soriano
IEOS, Institute of Experimental Endocrinology and Oncology "G. Salvatore", National Research Council, Naples, Italy.
Antonella
A
Monticelli
IEOS, Institute of Experimental Endocrinology and Oncology "G. Salvatore", National Research Council, Naples, Italy.|Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
Ornella
O
Affinito
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
Sergio
S
Cocozza
IEOS, Institute of Experimental Endocrinology and Oncology "G. Salvatore", National Research Council, Naples, Italy.
Mariastella
M
Zannini
D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D002460:Cell Line; D045744:Cell Line, Tumor; D018284:Cystadenocarcinoma, Serous / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D004847:Epithelial Cells / Q000378:metabolism*; D005187:Fallopian Tubes / Q000166:cytology / Q000378:metabolism; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods; D063990:Gene Ontology; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006801:Humans; D060787:Neoplasm Grading; D010051:Ovarian Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D000072636:PAX8 Transcription Factor / Q000235:genetics* / Q000378:metabolism; D034622:RNA Interference; D015398:Signal Transduction / Q000235:genetics*
D014408:Biomarkers, Tumor; D000072636:PAX8 Transcription Factor; C083325:PAX8 protein, human
PAX8; RNA-seq; fallopian tube secretory epithelial cells; ovarian cancer; transcriptional networks